Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma

Reis, Sara Rhaissa Rezende do; Helal-Neto, Edward; Silva, Aline Oliveira da; Pinto, Suyene Rocha; Portilho, Filipe Leal; Siqueira, Luciana Betzler de Oliveira; Alencar, Luciana Magalhães Rebêlo; Dahoumane, Si Amar; Alexis, Frank; Ricci-Júnior, Eduardo; Santos-Oliveira, Ralph

doi:10.1007/s11095-021-02999-w

Cited by 27 publications

(17 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the size, PdI, and ζ potential values of the formulations prepared with different methods (M1–3) were compared, no significant difference was found ( p < 0.05). Also, it is important to notice that a PdI value less than 0.3 represents a monodispersive behavior of the nanoparticles and corroborates the use for pharmaceutical products. , …”

Section: Resultsmentioning

confidence: 63%

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals

et al. 2022

Self Cite

View full text Add to dashboard Cite

The necessity of new drugs for lung cancer therapy and imaging is increasing each day. The development of new drugs that are capable of reaching the tumor with specificity and selectivity is required. In this direction, the design of nanoparticles for tumor therapy represents an important alternative. The aim of this study was to develop, characterize, and evaluate target-specific atezolizumab-conjugated poly(lactic acid)/poly(vinyl alcohol) (PLA/PVA) nanoparticles as pharmaceutical fragment candidates for new radiopharmaceuticals. For this purpose, PLA/PVA nanoparticle formulations were prepared by the double emulsification/solvent evaporation method with a high-speed homogenizer. A special focus was oriented to the selection of a suitable method for modification of the nanoparticle surface with a monoclonal antibody. For this purpose, atezolizumab was bound to the nanoparticles during the preparation by solvent evaporation or either by adsorption or covalent binding. PLA/PVA/atezolizumab nanoparticles are characterized by dynamic light scattering, Raman spectroscopy, scanning electron microscopy, and atomic force microscopy. An in vitro assay was performed to evaluate the antibody binding efficiency, stability, and cytotoxicity [A549 (lung cancer cell) and L929 (healthy fibroblast cell)]. The results showed that a spherical nanoparticle with a size of 230.6 ± 1.768 nm and a ζ potential of −2.23 ± 0.55 mV was produced. Raman spectroscopy demonstrated that the monoclonal antibody was entrapped in the nanoparticle. The high antibody binding efficiency (80.58%) demonstrated the efficacy of the nanosystem. The cytotoxic assay demonstrated the safety of the nanoparticle in L929 and the effect on A549. In conclusion, PLA/PVA/atezolizumab nanoparticles can be used as drug delivery systems for lung cancer diagnosis and therapy.

show abstract

Section: Resultsmentioning

confidence: 63%

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nanoparticulate formulations with a low zeta potential cannot maintain their stable state. In such cases, these nanoparticulate formulations should be stored in lyophilized form rather than liquid suspension and reconstituted just before use . The zeta potential value can influence the nanosystems to undergo phagocytosis.…”

Section: Discussionmentioning

confidence: 99%

“…In such cases, these nanoparticulate formulations should be stored in lyophilized form rather than liquid suspension and reconstituted just before use. 33 The zeta potential value can influence the nanosystems to undergo phagocytosis. Nanoparticles with near-zero zeta potential undergo lower phagocytic uptake compared to nanoparticles with a positive zeta potential.…”

Section: Discussionmentioning

confidence: 99%

Preparation and Evaluation of Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles Using the Quality by Design Approach

et al. 2022

View full text Add to dashboard Cite

The aim of the study was to prepare and evaluate the potential use of poly(lactic acid)/poly(vinyl alcohol) (PLA/PVA) nanoparticle formulations as a drug delivery system. The nanoparticle formulations were successfully developed by the double emulsification/solvent evaporation method. The developed formulations were optimized using the quality by design approach of the ICH Q8 (Pharmaceutical Development) guideline. In the studies, the effects of emulsifying devices, evaporation technique, centrifugation effect, and polymer concentrations on the physicochemical parameters of the formulations were investigated to obtain the best results. Furthermore, the prepared formulations were evaluated for clarity, particle size, distribution, zeta potential, surface and morphological features, preparation efficiency, and long-term stability. Based on the obtained results, the nanoparticle formulation containing 12.5% PLA, 1% primer, and seconder PVA has a suitable particle size (181.7 ± 2.194 nm) and distribution (0.104 ± 0.049), zeta potential (−0.88 ± 0.45 mV), and high preparation efficiency (65.38%), and nanoparticles were spherical, had a smooth surface, and were stable up to 12 months. In conclusion, this novel formulation can be used as a potential drug delivery system.

show abstract

“…In an effort to fight against melanoma resistance and generate synergistic effects from different mechanism of actions, dacarbazine was coencapsulated into nanoparticles with another compound, such as zinc phthalocyanine, 199 alltrans retinoic acid, 200 or into liposomes with eugenol. 201 In the codelivery with zinc phthalocyanine for photodynamic therapy of melanoma, 199 dacarbazine was incorporated into nanoparticles of poly(vinyl) alcohol and poly(lactic acid) using the double emulsion technique. The resulted formulation expressed synergistic effects in reducing the side effects of dacarbazine and the drug resistance on MV3 melanoma cells, both in vitro and in vivo.…”

Section: Prospects For Advanced Delivery Of Approved Drugs In the Tre...mentioning

confidence: 99%

Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma

et al. 2022

View full text Add to dashboard Cite

Melanoma is one of the most severe cancerous diseases. The cells employ multiple signaling pathways, such as ERK, HGF/c-MET, WNT, and COX-2 to cause the cell proliferation, survival, and metastasis. Treatment of melanoma, including surgery, chemotherapy, immunotherapy, radiation, and targeted therapy, is based on 4 major or 11 substages of the disease. Fourteen drugs, including dacarbazine, interferon α-2b, interleukin-12, ipilimumab, peginterferon α-2b, vemurafenib, trametinib, talimogene laherparepvec, cobimetinib, pembrolizumab, dabrafenib, binimetinib, encorafenib, and nivolumab, have been approved by the FDA for the treatment of melanoma. All of them are in conventional dosage forms of injection solutions, suspensions, oral tablets, or capsules. Major drawbacks of the treatment are side effects of the drugs and patients' incompliance to them. These are consequences of high doses and long-term treatments for the diseases. Currently more than 350 NCI-registered clinical trials are being carried out to treat advanced and/or metastatic melanoma using novel treatment methods, such as immune cell therapy, cancer vaccines, and new therapeutic targets. In addition, novel delivery systems using biomaterials of the approved drugs have been developed attempting to increase the drug delivery, targeting, stability, bioavailability, thus potentially reducing the toxicity and increasing the treatment effectiveness. Nanoparticles and liposomes have been emerging as advanced delivery systems which can improve drug stability and systemic circulation time. In this review, the most recent findings in the options for treatment and development of novel drug delivery systems for the treatment of melanoma are comprehensively discussed.

show abstract

Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma

Cited by 27 publications

References 65 publications

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals

Atezolizumab-Conjugated Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles as Pharmaceutical Part Candidates for Radiopharmaceuticals

Preparation and Evaluation of Poly(lactic acid)/Poly(vinyl alcohol) Nanoparticles Using the Quality by Design Approach

Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma

Contact Info

Product

Resources

About